Ning YANG, Tao HE, Wenxi ZHANG, Yiqiao XING

Exogenous erythropoietin aggravates retinal neovascularizationin a murine model of proliferative retinopathy

Background/aim: Erythropoietin (EPO) has been proven recently to be a critical mediator in retinal neovascularization (RNV). Previous studies have indicated that the use of recombinant human EPO (rEPO) is a high risk factor in the development of retinopathy of prematurity. In this study, we aimed to investigate the effect of rEPO administration on RNV and its underlying mechanism in a mouse model of oxygen-induced retinopathy (OIR). Materials and methods: A murine model of OIR was used to generate RNV. After daily intraperitoneal injection of rEPO from postnatal day 12 (P12), mice were euthanized at P17. Whole-mount retina staining was used to indicate the nonperfused area and neovascularization tufts. Preretinal neovascular cells were calculated through hematoxylin and eosin staining. The expression levels of vascular endothelial growth factor (VEGF) and inducible nitric oxide synthase (iNOS) were detected via western blot analysis. Results: We found that injection of rEPO promoted the severity of RNV. The areas of neovascular tufts and preretinal neovascular cells were increased after administration of rEPO. When mice were injected with rEPO, a dose-dependent upregulation in VEGF and iNOS was observed. Conclusion: The study indicates the proangiogenic role of EPO, suggesting that rEPO contributes to the pathogenesis of RNV.

PDF

___

1. Shah PK, Prabhu V, Karandikar SS, Ranjan R, Narendran V, Kalpana N. Retinopathy of prematurity: past, present and future. World J Clin Pediatr 2016; 5: 35-46.
2. Darlow BA. Retinopathy of prematurity: new developments bring concern and hope. J Paediatr Child Health 2015; 51: 765- 770.
3. Eldweik L, Mantagos IS. Role of VEGF inhibition in the treatment of retinopathy of prematurity. Semin Ophthalmol 2016; 31: 163-168.
4. Sapieha P, Hamel D, Shao Z, Rivera JC, Zaniolo K, Joyal JS, Chemtob S. Proliferative retinopathies: angiogenesis that blinds. Int J Biochem Cell Biol 2010; 42: 5-12.
5. Chen J, Smith LE. Retinopathy of prematurity. Angiogenesis 2007; 10: 133-140.
6. Stenson BJ. Oxygen targets for preterm infants. Neonatology 2013; 103: 341-345.
7. Cavallaro G, Filippi L, Bagnoli P, La Marca G, Cristofori G, Raffaeli G, Padrini L, Araimo G, Fumagalli M, Groppo M et al. The pathophysiology of retinopathy of prematurity: an update of previous and recent knowledge. Acta Ophthalmol 2014; 92: 2-20.
8. Aher SM, Ohlsson A. Late erythropoietin for preventing red blood cell transfusion in preterm and/or low birth weight infants. Cochrane Database Syst Rev 2014; 4: CD004868.
9. Rudzinska IM, Kornacka MK, Pawluch R. Treatment with human recombinant erythropoietin and frequency of retinopathy of prematurity. Przegl Lek 2002; 59 (Suppl. 1): 83- 85 (in Polish with abstract in English).
10. Watanabe D, Suzuma K, Matsui S, Kurimoto M, Kiryu J, Kita M, Suzuma I, Ohashi H, Ojima T, Murakami T et al. Erythropoietin as a retinal angiogenic factor in proliferative diabetic retinopathy. N Engl J Med 2005; 353: 782-792.
11. Romagnoli C, Tesfagabir MG, Giannantonio C, Papacci P. Erythropoietin and retinopathy of prematurity. Early Hum Dev 2011; 87 (Suppl. 1): S39-42.
12. Chen J, Connor KM, Aderman CM, Willett KL, Aspegren OP, Smith LE. Suppression of retinal neovascularization by erythropoietin siRNA in a mouse model of proliferative retinopathy. Invest Ophthalmol Vis Sci 2009; 50: 1329-1335.
13. Chou HH, Chung MY, Zhou XG, Lin HC. Early erythropoietin administration does not increase the risk of retinopathy in preterm infants. Pediatr Neonatol 2017; 58: 48-56.
14. Suk KK, Dunbar JA, Liu A, Daher NS, Leng CK, Leng JK, Lim P, Weller S, Fayard E. Human recombinant erythropoietin and the incidence of retinopathy of prematurity: a multiple regression model. J AAPOS 2008; 12: 233-238.
15. Smith LE, Wesolowski E, McLellan A, Kostyk SK, DAmato R, Sullivan R, DAmore PA. Oxygen-induced retinopathy in the mouse. Invest Ophthalmol Vis Sci 1994; 35: 101-111.
16. Li Z, He T, Du K, Xing YQ, Run YM, Yan Y, Shen Y. Inhibition of oxygen-induced ischemic retinal neovascularization with adenoviral 15-lipoxygenase-1 gene transfer via up-regulation of PPAR-gamma and down-regulation of VEGFR-2 expression. PLoS One 2014; 9: e85824.
17. Connor KM, Krah NM, Dennison RJ, Aderman CM, Chen J, Guerin KI, Sapieha P, Stahl A, Willett KL, Smith LE. Quantification of oxygen-induced retinopathy in the mouse: a model of vessel loss, vessel regrowth and pathological angiogenesis. Nat Protoc 2009; 4: 1565-1573.
18. Jo H, Jung SH, Kang J, Yim HB, Kang KD. Sulodexide inhibits retinal neovascularization in a mouse model of oxygeninduced retinopathy. BMB Rep 2014; 47: 637-642.
19. Aher SM, Ohlsson A. Early versus late erythropoietin for preventing red blood cell transfusion in preterm and/or low birth weight infants. Cochrane Database Syst Rev 2012; 10: CD004865.
20. Chen J, Connor KM, Aderman CM, Smith LE. Erythropoietin deficiency decreases vascular stability in mice. J Clin Invest 2008; 118: 526-533.
21. Slusarski JD, McPherson RJ, Wallace GN, Juul SE. High-dose erythropoietin does not exacerbate retinopathy of prematurity in rats. Pediatr Res 2009; 66: 625-630.
22. Nagy JA, Senger DR. VEGF-A, cytoskeletal dynamics, and the pathological vascular phenotype. Exp Cell Res 2006; 312: 538- 548.
23. Logue OC, McGowan JW, George EM, Bidwell GL 3rd. Therapeutic angiogenesis by vascular endothelial growth factor supplementation for treatment of renal disease. Curr Opin Nephrol Hypertens 2016; 25: 404-409.
24. Sato T, Kusaka S, Shimojo H, Fujikado T. Vitreous levels of erythropoietin and vascular endothelial growth factor in eyes with retinopathy of prematurity. Ophthalmology 2009; 116: 1599-1603.
25. McVicar CM, Colhoun LM, Abrahams JL, Kitson CL, Hamilton R, Medina RJ, Durga D, Gardiner TA, Rudd PM, Stitt AW. Differential modulation of angiogenesis by erythropoiesisstimulating agents in a mouse model of ischaemic retinopathy. PLoS One 2010; 5: e11870.
26. Carreau A, Kieda C, Grillon C. Nitric oxide modulates the expression of endothelial cell adhesion molecules involved in angiogenesis and leukocyte recruitment. Exp Cell Res 2011; 317: 29-41.
27. Iyer AK, Ramesh V, Castro CA, Kaushik V, Kulkarni YM, Wright CA, Venkatadri R, Rojanasakul Y, Azad N. Nitric oxide mediates bleomycin-induced angiogenesis and pulmonary fibrosis via regulation of VEGF. J Cell Biochem 2015; 116: 2484-2493.
28. Cassini-Vieira P, Araujo FA, da Costa Dias FL, Russo RC, Andrade SP, Teixeira MM, Barcelos LS. iNOS activity modulates inflammation, angiogenesis, and tissue fibrosis in polyetherpolyurethane synthetic implants. Mediators Inflamm 2015; 2015: 138461.
29. Sennlaub F, Courtois Y, Goureau O. Inducible nitric oxide synthase mediates the change from retinal to vitreal neovascularization in ischemic retinopathy. J Clin Invest 2001; 107: 717-725.
30. Lechner M, Lirk P, Rieder J. Inducible nitric oxide synthase (iNOS) in tumor biology: the two sides of the same coin. Semin Cancer Biol 2005; 15: 277-289.
31. He T, Ai M, Zhao XH, Xing YQ. Inducible nitric oxide synthase mediates hypoxia-induced hypoxia-inducible factor-1 alpha activation and vascular endothelial growth factor expression in oxygen-induced retinopathy. Pathobiology 2007; 74: 336-343.
32. Zhang Q, Zhang J, Guan Y, Zhang S, Zhu C, Xu GT, Wang L. Suppression of retinal neovascularization by the iNOS inhibitor aminoguanidine in mice of oxygen-induced retinopathy. Graefes Arch Clin Exp Ophthalmol 2009; 247: 919-927.
33. Holstein JH, Orth M, Scheuer C, Tami A, Becker SC, Garcia P, Histing T, Morsdorf P, Klein M, Pohlemann T et al. Erythropoietin stimulates bone formation, cell proliferation, and angiogenesis in a femoral segmental defect model in mice. Bone 2011; 49: 1037-1045.
34. Galeano M, Altavilla D, Bitto A, Minutoli L, Calo M, Lo Cascio P, Polito F, Giugliano G, Squadrito G, Mioni C et al. Recombinant human erythropoietin improves angiogenesis and wound healing in experimental burn wounds. Crit Care Med 2006; 34: 1139-11461